TB treatment: New shorter regimen identified in trial
by Press Release from Outbreak News Today on (#59BKX)
By NewsDesk @bactiman63 Results from an international, randomized, controlled clinical trial indicate that a four-month daily treatment regimen containing high-dose, or optimized," rifapentine with moxifloxacin is as safe and effective as the existing standard six-month daily regimen at curing drug-susceptible tuberculosis (TB) disease. This regimen is the first successful short-course treatment regimen for drug-susceptible TB disease [...]
The post TB treatment: New shorter regimen identified in trial appeared first on Outbreak News Today.